Navigation Links
Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
Date:4/7/2008

ROCKVILLE, Md., April 7, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the retirement of Ronald E. Cape, Ph.D. as Director, effective June 5, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Dr. Cape has been a Director of EntreMed since 2003, and has been instrumental in helping the Company chart its path forward in multi-mechanism oncology drugs. Dr. Cape was the co-founder, Chairman and CEO of Cetus Corporation, a world leader and pioneer in genetic engineering, including the discovery and development of the polymerase chain reaction (PCR), for which Cetus scientist Kary Mullis received the Nobel Prize. Cetus later merged with Chiron Corporation. Dr. Cape was the founding chairman of Darwin Molecular Corporation, which was later sold to Chiroscience plc. He was also a founding member of the Biotechnology Industry Organization and served as its President for three years.

Dr. Cape is a fellow of the American Academy of Arts and Sciences, the American Academy of Microbiology and the American Association for the Advancement of Science. He is the recipient of many awards, including the 2007 Biotechnology Heritage Award, and has held dozens of prestigious board positions in the public and private sectors. In recent years, Dr. Cape has been an investor in the field of biotechnology and a board member of various public and private companies. He has also served on the boards of Princeton University, Rockefeller University, the Whitehead Institute at MIT, and the Board of Regents of the NIH National Library of Medicine.

In announcing his pending retirement, Dr. Cape commented, "I am pleased to have served on the EntreMed Board during its rebuilding period. The Company has promising programs that are making good progress, but I would now like to spend more time with my family and friends. I wish everyone at EntreMed continued progress."

EntreMed Board Chairman, Michael M. Tarnow commented, "Dr. Cape has been a distinguished member of our Board since he joined in 2003. He has been involved in the biotech industry virtually from the beginning, and he has participated actively in its development since those early days. His valuable contributions to the field of biotechnology and his contribution to EntreMed are hallmarks of his leadership and commitment to the industry. We are honored to have had the opportunity to draw from Dr. Cape's vast knowledge and sage advice. While his service will be missed, we wish him all the best in his retirement."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. International Soccer Superstar Ronaldinho Signs With Nutrilite(TM)
2. MCM Completes Westwood Replacement Hospital - Ronald Reagan UCLA Medical Center
3. Philadelphia Ronald McDonald House(R) at Front & Erie Celebrates Grand Opening
4. Mayo Clinics Dr. Ronald C. Petersen Awarded Leon Thal Prize for Excellence in Dementia Research
5. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
6. St. Christophers Foundation For Children Ronald McDonald(R) Care Mobile Making Tri-State Visits to Provide Dental Care to Children at No Cost
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. East Ridge Retirement Village Announces Enhancement Plan
9. Increased Heart Risk Seen for Retired NFL Players
10. Mayo Clinic finds retired NFL players at increased risk for heart problems
11. AARP Deeply Disappointed by Supreme Court Decision on Retiree Health Care Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled to ... the most effective tattoo removal today, Dr. Bentkover is the only doctor in Central ... the PicoSure has been approved by the Food and Drug Administration (FDA) as a ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... Feb. 4, 2016  Montoya Love is recognized by ... field of Pharmaceuticals. Montoya is the Regulatory Systems Operations ... Manufacturing and selling a ... Dickinson provides healthcare institutions, clinical laboratories and life ... countries across the globe. ...
(Date:2/4/2016)... (NASDAQ: OMCL ), a leading provider of medication ... results for its fiscal year and fourth quarter ended ... GAAP results: Revenue for the fourth quarter of ... from the third quarter of 2015, and up $8.8 ... Revenue for the year ended December 31, 2015 was $484.6 ...
Breaking Medicine Technology: